UnicoCell Biomed Co (TPE:6794) Marketable Securities: NT$652.37 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:6794 UnicoCell Biomed Co Ltd TPE:6794
81 GF Score
Price NT$76.90
GF Value NT$81.05
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is UnicoCell Biomed Co Marketable Securities?

UnicoCell Biomed Co TPE:6794 -0.65% 81 Marketable Securities is NT$652.37 Mil as of Mar. 2026. GuruFocus rates TPE:6794 with a GF Score™ of 81/100 and a GF Value™ of NT$81.05 (Fairly Valued). The stock has 2 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. UnicoCell Biomed Co's Marketable Securities for the quarter that ended in Mar. 2026 was NT$652.37 Mil.

UnicoCell Biomed Co's annual Marketable Securities increased from Dec. 2023 (NT$457.38 Mil) to Dec. 2024 (NT$543.95 Mil) and increased from Dec. 2024 (NT$543.95 Mil) to Dec. 2025 (NT$711.18 Mil).

UnicoCell Biomed Co  (TPE:6794) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

UnicoCell Biomed Co Marketable Securities Related Terms

UnicoCell Biomed Co Marketable Securities Historical Data

* Premium members only.

The historical data trend for UnicoCell Biomed Co's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

UnicoCell Biomed Co Marketable Securities Chart

UnicoCell Biomed Co Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only 10.17 160.25 457.38 543.95 711.18

UnicoCell Biomed Co Quarterly Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 488.98 555.38 550.37 711.18 652.37
TPE:6794
81GF Score
UnicoCell Biomed Co Ltd TPE:6794
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

UnicoCell Biomed Co Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of NT$652.37 Mil mean?
UnicoCell Biomed Co (TPE:6794) has a Marketable Securities of NT$652.37 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on UnicoCell Biomed Co and its competitors.
Is UnicoCell Biomed Co's Marketable Securities too high?
UnicoCell Biomed Co's current Marketable Securities is NT$652.37 Mil. Overall, UnicoCell Biomed Co has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does UnicoCell Biomed Co's Marketable Securities compare to VRTX and REGN?
UnicoCell Biomed Co's Marketable Securities of NT$652.37 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on UnicoCell Biomed Co and its competitors. UnicoCell Biomed Co's current Marketable Securities is NT$652.37 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is UnicoCell Biomed Co stock overvalued right now?
Based on GuruFocus' analysis, UnicoCell Biomed Co (TPE:6794) is currently considered Fairly Valued. The stock's GF Value™ is NT$81.05, compared to a current price of NT$76.90 — trading 5.1% below its estimated fair value. The current Marketable Securities is NT$652.37 Mil. UnicoCell Biomed Co's overall GF Score™ is 81/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For UnicoCell Biomed Co (TPE:6794), the current Marketable Securities is NT$652.37 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is UnicoCell Biomed Co (TPE:6794) Overvalued in 2026?

Based on GuruFocus' analysis, UnicoCell Biomed Co stock appears to be undervalued. The current stock price of NT$76.90 is trading 5.1% below its estimated GF Value™ of NT$81.05. GuruFocus considers UnicoCell Biomed Co to be Fairly Valued.

Key valuation signals for TPE:6794:

  • Marketable Securities: NT$652.37 Mil
  • GF Value™: NT$81.05 vs. price of NT$76.90 (5.1% below fair value)
  • GF Score™: 81/100 with 2 warning signs

No single metric tells the full story. See the TPE:6794 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

UnicoCell Biomed Co Business Description

Address Minquan East Road, 5th Floor, No. 13-20, Section 6, Neihu District, Taipei, TWN, 11494
UnicoCell Biomed Co Ltd is engaged in new drug R&D and human tissue-derived stem cell inspection and testing, extraction, storage, and technology R&D. It focuses on researching and developing stem cells and its derived technology for medical applications, with the goal of advancing human health and improving quality of life. The company's products include Allogeneic Adipose Stem Cell Bank, Autologous Stem Cell Therapy, Conditioned Medium, Mass Production and CDMO, Cryogenic Vial (Class 2 Medical Device), and Testing services. It operates in single segment. Geographically, its operations are spread across Taiwan, Japan and Others with Taiwan generating the majority of the revenue.
81GF Score

Get the complete analysis for TPE:6794

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$76.90
Price
NT$81.05
GF Value